Clinical trial NCT05737810: Attitudes and Unmet Needs Among Type 2 Diabetes Patients
Official title: Attitudes and Unmet Needs Among Type 2 Diabetes Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type 2 Diabetes
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2023-02-21
Enrollment: 700
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The main purpose of this study is to explore experiences and understand the unmet needs of people with Type 2 Diabetes among those who are being managed with basal insulin and those who are insulin naïve in order to understand perspectives for a once weekly insulin option; including any potential barriers to being managed with insulin therapy overall.

Brief summary: The main purpose of this study is to explore experiences and understand the unmet needs of people with Type 2 Diabetes (T2D) among those who are being managed with basal insulin and those who are insulin naïve in order to understand perspectives for a once weekly insulin option; including any potential barriers to being managed with insulin therapy overall. Study participants will be recruited to complete a 15-minute self-administered online survey.


Eligibility criteria: Inclusion Criteria:

1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
2. Male or female, age above or equal between 18 to 65 years at the time of signing informed consent.
3. Diagnosed with T2D and currently treating T2D with at least one medication
4. Insulin user that is not using insulin pump
5. Lives in a target country

Exclusion Criteria:

1. Previous participation in this study. Participation is defined as having given informed consent in this study
2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
3. Does not meet inclusion criteria requirements

Primary outcomes:
measure: Current medication burden
timeFrame: At the time of survey response (Day1)
measure: Injection perceptions
timeFrame: At the time of survey response (Day1)
measure: Attitudes regarding T2D overall
timeFrame: At the time of survey response (Day1)
measure: Attitudes regarding T2D treatment
timeFrame: At the time of survey response (Day1)
measure: Attitudes regarding insulin icodec
timeFrame: At the time of survey response (Day1)
Secondary outcomes:
Other outcomes:
Locations:
city: Sydney
country: Australia
facility: Novo Nordisk Investigational Site
city: Chartres
country: France
facility: Novo Nordisk Investigational Site
city: Bengaluru
country: India
facility: Novo Nordisk Investigational Site
city: Seoul
country: Korea, Republic of
facility: Novo Nordisk Investigational Site
city: Mexico City
country: Mexico
facility: Novo Nordisk Investigational Site
city: Riyadh
country: Saudi Arabia
facility: Novo Nordisk Investigational Site
city: London
country: United Kingdom
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Clinical Transparency (dept. 2834)
role: STUDY_DIRECTOR
References: